Literature DB >> 19165709

ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.

M Daood1, C Tsai, M Ahdab-Barmada, J F Watchko.   

Abstract

P-glycoprotein (P-gp/ABCB1), multidrug resistance associated protein 1 (MRP1/ABCC1), and breast cancer resistance protein (BCRP/ABCG2) are plasma membrane efflux pumps that limit the intracellular uptake and retention of numerous lipophilic, amphipathic xeno- and endobiotics. Little is known about the neonatal and developmental expression of P-gp/ABCB1, MRP1/ABCC1, and BCRP/ABCG2 in the human central nervous system (CNS), therefore post-mortem CNS tissue from infants born at 22 (0/7)-42 (0/7) weeks of gestation and adults was immunostained to determine their ontogeny and cellular localization. P-gp/ABCB1 immunostaining was observed in microvessel endothelial cells as early as 22 (0/7) weeks, increasing in prevalence and intensity with maturation, and later in gestation in large pyramidal neurons. MRP1/ABCC1 immunostaining was prominent early in the choroid plexus and ventricular ependyma, and noted later in large pyramidal neurons. BCRP/ABCG2 expression was limited to microvessel endothelial cells. P-gp/ABCB1, MRP1/ABCC1 and BCRP/ABCG2 in adult brain matched term newborn CNS but with more intense immunostaining. We conclude that P-gp/ABCB1, MRP1/ABCC1, and BCRP/ABCG2 are expressed in a developmental, cell specific, fashion in the human CNS. The complementary pattern of P-gp/ABCB1 and BCRP/ABCG2 at the blood-brain with MRP1/ABCC1 at the blood-CSF barriers may limit CNS uptake and retention of drugs and toxins in neonates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19165709      PMCID: PMC2821654          DOI: 10.1055/s-0028-1103272

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  48 in total

1.  Preparation of an antibody recognizing both human and rodent MRP1.

Authors:  C Fernetti; L Pascolo; E Podda; R Gennaro; M Stebel; C Tiribelli
Journal:  Biochem Biophys Res Commun       Date:  2001-11-09       Impact factor: 3.575

2.  P-glycoprotein expression in mouse brain increases with maturation.

Authors:  Catherine E Tsai; Monica J Daood; Robert H Lane; Thor W R Hansen; Elisa M Gruetzmacher; Jon F Watchko
Journal:  Biol Neonate       Date:  2002-01

Review 3.  P-glycoprotein and bilirubin disposition.

Authors:  J F Watchko; M J Daood; B Mahmood; K Vats; C Hart; M Ahdab-Barmada
Journal:  J Perinatol       Date:  2001-12       Impact factor: 2.521

4.  Functional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes.

Authors:  X Declèves; A Regina; J L Laplanche; F Roux; B Boval; J M Launay; J M Scherrmann
Journal:  J Neurosci Res       Date:  2000-06-01       Impact factor: 4.164

5.  The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice.

Authors:  D R Johnson; R A Finch; Z P Lin; C J Zeiss; A C Sartorelli
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

6.  Localisation of breast cancer resistance protein in microvessel endothelium of human brain.

Authors:  Hiran C Cooray; Colin G Blackmore; Lynn Maskell; Margery A Barrand
Journal:  Neuroreport       Date:  2002-11-15       Impact factor: 1.837

7.  Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies.

Authors:  G L Scheffer; M Kool; M Heijn; M de Haas; A C Pijnenborg; J Wijnholds; A van Helvoort; M C de Jong; J H Hooijberg; C A Mol; M van der Linden; J M de Vree; P van der Valk; R P Elferink; P Borst; R J Scheper
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

8.  Expression of the multidrug resistance P glycoprotein (Pgp) and multidrug resistance associated protein (MRP1) in Down syndrome brains.

Authors:  E Engidawork; J C Roberts; R Hardmeier; R J Scheper; G Lubec
Journal:  J Neural Transm Suppl       Date:  2001

9.  Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy.

Authors:  S M Sisodiya; W-R Lin; B N Harding; M V Squier; M Thom
Journal:  Brain       Date:  2002-01       Impact factor: 13.501

10.  Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material.

Authors:  Julio E Diestra; George L Scheffer; Isabel Català; Marc Maliepaard; Jan H M Schellens; Rik J Scheper; Jose R Germà-Lluch; Miguel A Izquierdo
Journal:  J Pathol       Date:  2002-10       Impact factor: 7.996

View more
  65 in total

1.  P-glycoprotein in the developing human blood-brain barrier.

Authors:  Jon F Watchko
Journal:  Pediatr Res       Date:  2016-01-12       Impact factor: 3.756

2.  Crigler-Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier.

Authors:  Kevin A Strauss; Charles E Ahlfors; Kyle Soltys; George V Mazareigos; Millie Young; Lauren E Bowser; Michael D Fox; James E Squires; Patrick McKiernan; Karlla W Brigatti; Erik G Puffenberger; Vincent J Carson; Hendrik J Vreman
Journal:  Hepatology       Date:  2020-02-05       Impact factor: 17.425

3.  Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant.

Authors:  Jessica K Roberts; Anna V Birg; Tong Lin; Vinay M Daryani; John C Panetta; Alberto Broniscer; Giles W Robinson; Amar J Gajjar; Clinton F Stewart
Journal:  Drug Metab Dispos       Date:  2016-04-06       Impact factor: 3.922

Review 4.  Drug transporters in the central nervous system.

Authors:  Bruno Stieger; Bo Gao
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

Review 5.  Multidrug Resistance Proteins (MRPs) and Cancer Therapy.

Authors:  Yun-Kai Zhang; Yi-Jun Wang; Pranav Gupta; Zhe-Sheng Chen
Journal:  AAPS J       Date:  2015-04-04       Impact factor: 4.009

Review 6.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

Review 7.  An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus.

Authors:  Lyrialle W Han; Chunying Gao; Qingcheng Mao
Journal:  Expert Opin Drug Metab Toxicol       Date:  2018-08-03       Impact factor: 4.481

8.  Neonatal pharmacology: extensive interindividual variability despite limited size.

Authors:  Cuneyt Tayman; Maisa Rayyan; Karel Allegaert
Journal:  J Pediatr Pharmacol Ther       Date:  2011-07

Review 9.  Toxicology of avermectins and milbemycins (macrocylic lactones) and the role of P-glycoprotein in dogs and cats.

Authors:  Valentina M Merola; Paul A Eubig
Journal:  Vet Clin North Am Small Anim Pract       Date:  2012-03       Impact factor: 2.093

10.  Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P-Glycoprotein) in endothelial cells of the blood-brain barrier in mutant superoxide dismutase 1-linked amyotrophic lateral sclerosis.

Authors:  Hisham Qosa; Jessica Lichter; Mark Sarlo; Shashirekha S Markandaiah; Kevin McAvoy; Jean-Philippe Richard; Michael R Jablonski; Nicholas J Maragakis; Piera Pasinelli; Davide Trotti
Journal:  Glia       Date:  2016-05-09       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.